drugset / Trial / NCT04667429

the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets

NCT04667429 ↗

Phase 1 Completed 57 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

Multiple Dose Safety, Tolerability, PK ,PD and Food Effect Study of HEC83518 in Healthy Subjects

Timeline

Start
2021-01-18
Primary completion
2021-07-09
Completion
2021-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC83518 Unknown 20 mg Oral
Subject HEC83518 Unknown 40 mg Oral
Subject HEC83518 Unknown 80 mg Oral

Indications